MYOSITIS AND MYOPATHIES: Edited by Hector Chinoy and Robert G. CooperThe diagnostic utility of autoantibodies in adult and juvenile myositisTansley, Sarah L.a; Betteridge, Zoe E.b; McHugh, Neil J.aAuthor Information aRoyal National Hospital for Rheumatic Diseases bUniversity of Bath, Bath, UK Correspondence to Neil J. McHugh, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath BA1 1RL, UK. Tel: +1225 463223; fax: +1225 473437; e-mail: Neil.McHugh@rnhrd.nhs.uk Current Opinion in Rheumatology: November 2013 - Volume 25 - Issue 6 - p 772-777 doi: 10.1097/01.bor.0000434664.37880.ac Buy Metrics Abstract Purpose of review The purpose of this study is to review recent advances in the diagnostic utility of autoantibodies in dermatomyositis. Recent findings Alternative nonspecialist testing methods have been developed for anti-transcription intermediary factor 1 gamma, anti-MDA5 and anti-nuclear matrix protein 2, which are potentially exploitable by any hospital laboratory. Although these have yet to be validated for diagnostic use, it is likely that testing for myositis-specific antibodies will soon become readily available. Summary The identification of myositis-specific autoantibodies provides both diagnostic and prognostic information and offers a unique opportunity to adopt a stratified approach to treatment. Their identification, in many cases, should prevent the need for invasive diagnostic tests such as muscle biopsy. © 2013 Lippincott Williams & Wilkins, Inc.